Ad Header



The Pulse of the Pharmaceutical Industry

Mylan teams up with Revance on biosimilar for Botox

Written by: | | Dated: Wednesday, February 28th, 2018


Mylan teams up with Revance on biosimilar for Botox


Mylan NV on Wednesday struck a licensing agreement with Revance Therapeutics Inc to develop a biosimilar of Allergan Plc’s blockbuster Botox wrinkle treatment.

The deal includes an upfront payment of $25 million to Revance​, Mylan said.

Revance’s own rival to Botox is not yet approved by the U.S. Food and Drug Administration. Revance reported positive Phase III data for its longer-lasting wrinkle treatment in December and said then that it planned to launch the drug in 2020, pending FDA approval.


(Reporting by Michael Erman; Editing by Susan Thomas)


Reuters source:

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2018 Focus: Top 10 Pipelines, Focused Value in Pharma, Agenda 2018 and MAHF!


Ad Right Bottom

Main Navigation